Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

22. Juli 2021 08:00 ET | Quelle: Catalyst Biosciences, Inc.

Catalyst Biosciences Announces First Patient Screened for CFI deficiency in its CB 4332 Screening and Natural History of Disease Studies

SOUTH SAN FRANCISCO, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced the screening of the first patient in its CFI-deficiency study in the CB 4332...
19. Juli 2021 16:01 ET | Quelle: Catalyst Biosciences, Inc.

Catalyst Biosciences Presents Four Posters at the International Society for Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress

SOUTH SAN FRANCISCO, Calif., July 19, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today presented four posters at the International Society for Thrombosis and Haemostasis...
14. Juli 2021 08:00 ET | Quelle: Catalyst Biosciences, Inc.

Catalyst Biosciences Announces Key Leadership Changes in its Ongoing Transition to an Integrated Protease Medicines Company

Grant Blouse, Ph.D., M.Sc. appointed chief scientific officer Tom Knudsen, DVM, Ph.D. promoted to senior vice president, corporate development Howard Levy, M.B.B.Ch, Ph.D., M.M.M. transitions to...
06. Juli 2021 08:00 ET | Quelle: Catalyst Biosciences, Inc.

Catalyst Biosciences Announces Presentations at the International Society on Thrombosis and Haemostasis

SOUTH SAN FRANCISCO, Calif., July 06, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced four poster presentations on marzaptacog alfa (activated) (MarzAA) and...
01. Juli 2021 08:00 ET | Quelle: Catalyst Biosciences, Inc.

Catalyst Biosciences to Host Research and Development Day on CB 4332 and Complement Programs

SOUTH SAN FRANCISCO, Calif., July 01, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that it will host a research and development day on its protease medicines...
28. Juni 2021 08:00 ET | Quelle: Catalyst Biosciences, Inc.

Catalyst Biosciences Receives FDA Fast Track Designation for Subcutaneous MarzAA for the Treatment of Episodic Bleeding in Factor VII Deficiency

SOUTH SAN FRANCISCO, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track...
10. Juni 2021 08:00 ET | Quelle: Catalyst Biosciences, Inc.

Catalyst Biosciences to Participate in Two Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that members of its executive management team will participate in fireside...
18. Mai 2021 08:00 ET | Quelle: Catalyst Biosciences, Inc.

Catalyst Biosciences Announces First Patient Dosed in Marzeptacog Alfa (Activated) Phase 1/2 Study in Factor VII Deficiency, Glanzmann Thrombasthenia and Hemophilia A treated with Hemlibra

SOUTH SAN FRANCISCO, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced the initiation of dosing in the Company's Phase 1/2 study (MAA-202) of...
13. Mai 2021 08:00 ET | Quelle: Catalyst Biosciences, Inc.

Catalyst Biosciences to Present at the Truist Securities Life Sciences Summit

SOUTH SAN FRANCISCO, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that members of its executive management team will participate in a fireside...
06. Mai 2021 08:00 ET | Quelle: Catalyst Biosciences, Inc.

Catalyst Biosciences Reports First Quarter 2021 Operating & Financial Results and Provides a Corporate Update

SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the first quarter ended March 31, 2021...

Vorherige Seite

Nächste Seite